The Challenge Of Immune Rejection For Allogeneic Cell Therapies 2022-08-05
By: Luis Borges, PhD, Chief Scientific Officer and Hy Levitsky, MD, Head of R&D, Century TherapeuticsAutologous, genetically engineered T cells expressing chimeric antigen receptors (CAR-T) have dramatically reshaped treatment of multiple hematologic malignancies. Despite their benefit, these indivi
Read More